The 'state' of beta-adrenoceptors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.Handbook of experimental pharmacology · 2024
   Review
2. Introduction: A Short History of Adrenoceptor Research.Handbook of experimental pharmacology · 2024
   Article
3. Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.Molecular pharmacology · 2014
   Article
4. Non-traditional roles of G protein-coupled receptors in basic cell biology.Molecular bioSystems · 2013
   Review
5. Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.PloS one · 2013
   Article
6. Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2011
   Article
7. The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor.Naunyn-Schmiedeberg's archives of pharmacology · 2011
   Article
8. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.Trends in pharmacological sciences · 2011
   Review
9. A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.PloS one · 2010
   Article
10. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.British journal of pharmacology · 2010
    Article
11. Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling.British journal of pharmacology · 2009
    Article
12. Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells.BMC pharmacology · 2008
    Article
13. A study of antagonist affinities for the human histamine H2 receptor.British journal of pharmacology · 2008
    Article
14. Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates.Trends in pharmacological sciences · 2007
    Review
15. ALpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta.British journal of pharmacology · 2004
    Article

Corrections and comments

• Comment on
  Atypical beta-adrenoceptors, different from beta 3-adrenoceptors and probably from the low-affinity state of beta 1-adrenoceptors, relax the rat isolated mesenteric artery.2003

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as